Sanofi Highlights the P-III (IMROZ) Study Data of Sarclisa for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Shots:
- The P-III (IMROZ) study data of Sarclisa (10mg/kg, IV, QW for 5wks. during the first 42-day cycle; Q2W in C2 to C4) + bortezomib (SC), lenalidomide (oral) & dexamethasone (IV) vs VRd in transplant-ineligible MM patients (n=446) was also published in the NEJM
- The study, as of Sep 2023 & 59.7mos. median follow-up, showed reduced disease progression or death risk by 40% with mPFS not attained vs 54.3mos., 63.2% vs 45.2% PFS at 60mos., CR in ~74.7% vs 64.1% of patients & MRD -ve CR in 55.5% vs 40.9% of them with a sustained MRD in 46.8% vs 24.3% for 12mos.
- Additionally, sBLA of Sarclisa-VRd for the above indication has been accepted & received the US FDA's priority review. Another submission under review across the EU
Ref: Globenewswire | Image: Sanofi
Related News:- Sanofi Reports the US FDA’s sBLA Acceptance of Sarclisa to Treat Transplant-Ineligible Newly Diagnosed Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
